全文获取类型
收费全文 | 1561篇 |
免费 | 167篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 18篇 |
妇产科学 | 9篇 |
基础医学 | 138篇 |
口腔科学 | 16篇 |
临床医学 | 53篇 |
内科学 | 146篇 |
皮肤病学 | 874篇 |
神经病学 | 18篇 |
特种医学 | 42篇 |
外科学 | 104篇 |
综合类 | 48篇 |
预防医学 | 39篇 |
眼科学 | 1篇 |
药学 | 91篇 |
1篇 | |
中国医学 | 36篇 |
肿瘤学 | 97篇 |
出版年
2023年 | 107篇 |
2022年 | 64篇 |
2021年 | 65篇 |
2020年 | 107篇 |
2019年 | 53篇 |
2018年 | 71篇 |
2017年 | 67篇 |
2016年 | 56篇 |
2015年 | 70篇 |
2014年 | 97篇 |
2013年 | 96篇 |
2012年 | 79篇 |
2011年 | 77篇 |
2010年 | 86篇 |
2009年 | 82篇 |
2008年 | 78篇 |
2007年 | 41篇 |
2006年 | 34篇 |
2005年 | 36篇 |
2004年 | 36篇 |
2003年 | 29篇 |
2002年 | 22篇 |
2001年 | 26篇 |
2000年 | 18篇 |
1999年 | 20篇 |
1998年 | 16篇 |
1997年 | 11篇 |
1996年 | 16篇 |
1995年 | 14篇 |
1994年 | 9篇 |
1993年 | 12篇 |
1992年 | 7篇 |
1990年 | 7篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1986年 | 12篇 |
1985年 | 8篇 |
1984年 | 5篇 |
1977年 | 4篇 |
1975年 | 4篇 |
1974年 | 3篇 |
1970年 | 4篇 |
1967年 | 3篇 |
1965年 | 4篇 |
1958年 | 7篇 |
1956年 | 4篇 |
1954年 | 3篇 |
1925年 | 2篇 |
1921年 | 4篇 |
排序方式: 共有1733条查询结果,搜索用时 93 毫秒
41.
A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
42.
43.
44.
45.
P. Gisondi S. Cazzaniga S. Chimenti A. Giannetti M. Maccarone M. Picardo G. Girolomoni L. Naldi Psocare Study Group 《Journal of the European Academy of Dermatology and Venereology》2013,27(1):e30-e41
Objective To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks after starting a new systemic psoriasis treatment for Psocare Registry enrollees. Design Prospective cohort study. Setting Italian public referral centres for psoriasis treatment. Patients First‐time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. Main outcome measure Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in serum levels (week 16) of total and low‐density lipoprotein cholesterol, triglycerides, aspartate amino transferase, alanine amino transferase and creatinine, as well as week‐16 cumulative incidences of new diagnoses of diabetes mellitus and arterial hypertension. Results Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or cyclosporine. Mean triglyceride levels also increased in efalizumab‐ and etanercept‐treated patients. Mean transaminase values increased in methotrexate‐treated patients, and mean aspartate amino transferase levels increased in infliximab‐treated patients. The average serum creatinine value increased in cyclosporine‐treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia (odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase (odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds ratios 3.31 and 2.88). Conclusion Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed. 相似文献
46.
47.
48.
Hidetoshi Takahashi Katsuhiko Satoh Akiyoshi Takagi Hajime Iizuka 《The Journal of dermatology》2017,44(9):1024-1026
Topical and systemic agents have dramatically improved the treatment efficacy of psoriasis. Few reports, however, exist describing the economic burden in Japanese psoriatic patients. The aim of the study was to evaluate the total costs as well as cost versus efficacy of topical and systemic treatments of psoriatic patients under the Japanese health insurance system. The retrospective study was performed from the database of our clinic, which is located in Hokkaido Prefecture. Cost and effectiveness of psoriatic patients were evaluated during the 12‐month period from April 2015 to March 2016. Data were collected and calculated for the total cost per year, treatment efficacy and cost versus efficacy. The mean total cost of topical corticosteroid treatment was ¥18 184/year and was lowest among the treatments. The systemic treatment with biologics was most expensive and the costs were over ¥400 000/year. Among the topical treatments, calcipotriol/betamethasone dipropionate was most expensive (¥34 693/year). However, cost versus efficacy was not significantly different from that of topical corticosteroid treatments. The cost of secukinumab was highest among all the treatments (¥631 600/year). However, treatment day per cost was lowest of all the psoriasis treatments. Biologics showed the highest cost than topical or systemic treatments. However, they showed most marked efficacy in terms of improving the psoriatic skin lesions. 相似文献
49.
Stefano Pulini Serena Rupoli Gaia Goteri Nicola Pimpinelli Renato Alterini Alberta Bettacchi Simonetta Mulattieri Paola Picardi Angela Tassetti Anna Rita Scortechini Giuseppe Fioritoni Pietro Leoni 《European journal of haematology》2009,82(3):184-193
Objectives: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg‐Doxo) in primary cutaneous T‐cell lymphomas, while in primary cutaneous B‐cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far. Methods: We performed a prospective phase II pilot clinical trial of Peg‐Doxo monotherapy (20 mg/m2) in PCBCLs. One patient had a marginal zone B‐cell lymphoma and four were affected by diffuse large B‐cell lymphoma‐leg type, all with widespread nodular lesions. Results: All the patients achieved a complete response (CR = 100%) in a short period of time (median 3 months), even when pretreated with radio‐chemotherapy. Two experienced a relapse. At follow‐up, one patient died for progressive disease; four are in CR after 5, 52, 63 and 69 months. As concerning the toxicity profile, the treatment was well‐tolerated, no one decreased or delayed the dose. The haematological toxicity was mild with only one case of grade III neutropenia; a patient showed a grade I neurotoxicity. Dermatological toxicity, in particular the palmar–plantar erythrodysesthesia, did not occurred, probably because of both the low dosages of Peg‐Doxo monotherapy and the oral prophylaxis with pyridoxine. Conclusions: In spite of the small number of patients, it emerges that monochemotherapy with Peg‐Doxo has a significantly high clinical activity and a good safety profile in PCBCLs, even in aggressive forms, compared with other therapeutic regimens, which are completely reviewed. It suggests the need of further investigations in this field. 相似文献
50.
Skin melanoma remains a highly prevalent and yet deadly form of cancer, with the exact degree of melanoma-associated mortality being strongly dependent upon the local tumor microenvironment. The exact composition of stromal and immune cells within this microenvironmental region has the potential to profoundly impact melanoma progression and prognosis. As such, the present study was designed with the goal of clarifying the predictive relevance of stromal and immune cell-related genes in melanoma patients through comprehensive bioinformatics analyses. We therefore analyzed melanoma sample gene expression within The Cancer Genome Atlas database and employed the ESTIMATE algorithm as a means of calculating both stromal and immune scores that were in turn used for identifying differentially expressed genes (DEGs). Subsequently, univariate analyses were used to detect DEGs associated with melanoma patient survival, and through additional functional enrichment analyses, we determined that these survival-related DEGs are largely related to inflammatory and immune responses. A prognostic signature comprised of 10 genes (IL15, CCL8, CLIC2, SAMD9L, TLR2, HLA.DQB1, IGHV1–18, RARRES3, GBP4, APOBEC3G) was generated. This 10-gene signature effectively separated melanoma patients into low- and high-risk groups based upon their survival. These low- and high-risk groups also exhibited distinct immune statuses and differing degrees of immune cell infiltration. In conclusion, our results offer novel insights into a number of microenvironment-associated genes that impact survival outcomes in melanoma patients, potentially highlighting these genes as viable therapeutic targets. 相似文献